Novartis’s Tasigna®

• Healthcare
• Pharma & Biotech
• Science
• Switzerland

Large, randomized Phase III studies demonstrate superiority of Novartis Tasigna® (nilotinib) compared to Glivec® (imatinib) in newly diagnosed Ph+ CML patients

ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus…